When to switch from cycle to TRT-cruise?

Medical decision based on persistent biological panel. Suggestive criteria: T total < 300 ng/dL at 3 months post-PCT after several cycles, LH < 2 IU/L (non-functional HPG axis), persistent hypogonadism symptoms (fatigue, low libido, depression), repeated unsuccessful PCT attempts. Coward 2013 documents ASIH in chronic users. Endocrinology consultation essential to confirm diagnosis and institute medically supervised TRT. Bhasin 2018 (Endocrine Society) frames indications and protocol.

Incompatible without support. TRT suppresses endogenous testosterone production and therefore spermatogenesis in a few months. To preserve fertility under TRT (Anawalt 2019, Liu 2002): hCG 250-500 IU 2× per week SC in parallel with testosterone to stimulate Leydig cells and maintain spermatogenesis. Alternative: enclomiphene (Androxal-like) 12.5-25 mg/d in monotherapy that maintains endogenous production. For users wishing to procreate, these protocols preserve reproductive function while ensuring satisfactory T levels.

Cardiovascular profile: cycle vs TRT?

Very different. TRT at physiological dose is cardio-neutral (Lincoff 2023, RCT TRAVERSE on 5,246 hypogonadic men at risk, 33-month follow-up). No significant increase in major cardio events vs placebo, slight increase in atrial fibrillation and venous thromboembolism (low incidence). Cumulated supraphysiological cycle: hypertension, severe dyslipidemia, left ventricular hypertrophy (Baggish 2017, Smit 2022). For users > 35 years or with cardio family history, clean TRT markedly more favorable than repeated cycles.

How many cycles before probable ASIH?

Variable per individual, but Coward 2013 and Rasmussen 2016 document cumulative risk increasing with: (1) number of total cycles (> 3-5 cumulated cycles), (2) duration of individual cycles (> 16 weeks), (3) strong-suppression compounds (nandrolone, trenbolone), (4) neglected or incomplete PCTs. Statistically, about 20-30% of chronic users (> 5 years of repeated cycles) switch to persistent hypogonadism requiring permanent TRT. To minimize: short cycles, clean PCTs, off-windows > 1.5× the on-block duration, regular biological monitoring.

TRT-cruise (clinical): 50-150 €/month per country and formula (testosterone + hCG + AI). Medical follow-up included if TRT prescribed. Classic bodybuilder cycle: 200-500 € during 12-16 weeks of blast (testo + compounds + AI + PCT), free during off. Over 12 months: TRT ≈ 1500 € constant; cycle = 800-1500 € with high concentration on blast periods. Short-term, cycle may seem cheaper if infrequent. Long-term (10+ years), clinical TRT is generally more economical and more predictable.

Does clean PCT guarantee recovery?

No, but maximizes chances. A well-conducted PCT (hCG 1500 IU EOD × 10 d + clomid 50/25/25/25 mg + nolvadex 40/20/20/20 mg over 4-6 weeks) allows 70-90% of users to recover endogenous T > 400 ng/dL at 3 months post-PCT (Rahnema 2014). But 10-30% develop partial or complete ASIH, particularly after long cycles or nandrolone/trenbolone. Negative predictive factors: age > 35 years, comorbidities, repeated cycles > 5, low pre-cycle baseline T. Systematic pre-cycle and post-PCT biological panel to identify at-risk users.

TRT in young user (< 30 years)?

Delicate question. If confirmed primary hypogonadism (Klinefelter, post-orchidectomy, etc.), lifelong TRT justified. If ASIH secondary to cycles, the decision of permanent TRT before 30 years commits the user to 50+ years of treatment with impacts (fertility, medical dependence, lifelong follow-up). Several endocrinologists recommend exhausting restart options (prolonged clomid, hCG, enclomiphene) before switching to permanent TRT. Specialist consultation essential to assess long-term benefit/constraint ratio.

Classic Cycle vs TRT-cruise: complete comparison (protocols, philosophies)

Q: TRT and fertility?

Incompatible without support. TRT suppresses endogenous testosterone production and therefore spermatogenesis in a few months. To preserve fertility under TRT (Anawalt 2019, Liu 2002): hCG 250-500 IU 2× per week SC in parallel with testosterone to stimulate Leydig cells and maintain spermatogenesis. Alternative: enclomiphene (Androxal-like) 12.5-25 mg/d in monotherapy that maintains endogenous production. For users wishing to procreate, these protocols preserve reproductive function while ensuring satisfactory T levels.

Q: Cardiovascular profile: cycle vs TRT?

Very different. TRT at physiological dose is cardio-neutral (Lincoff 2023, RCT TRAVERSE on 5,246 hypogonadic men at risk, 33-month follow-up). No significant increase in major cardio events vs placebo, slight increase in atrial fibrillation and venous thromboembolism (low incidence). Cumulated supraphysiological cycle: hypertension, severe dyslipidemia, left ventricular hypertrophy (Baggish 2017, Smit 2022). For users > 35 years or with cardio family history, clean TRT markedly more favorable than repeated cycles.

Q: TRT in young user (< 30 years)?

Delicate question. If confirmed primary hypogonadism (Klinefelter, post-orchidectomy, etc.), lifelong TRT justified. If ASIH secondary to cycles, the decision of permanent TRT before 30 years commits the user to 50+ years of treatment with impacts (fertility, medical dependence, lifelong follow-up). Several endocrinologists recommend exhausting restart options (prolonged clomid, hCG, enclomiphene) before switching to permanent TRT. Specialist consultation essential to assess long-term benefit/constraint ratio.

Classic Cycle vs TRT-cruise: complete comparison (protocols, philosophies)

Critère	cycle-protocol	trt-cruise
Duration	10-16 wk (cycle) + PCT	Permanent (TRT)
Testo dose	300-600 mg/week (supraphysio)	100-200 mg/week (physio)
Cardiovascular profile	Variable per dose	Neutral (Lincoff 2023)
Fertility	Recoverable post-PCT	Suppressed (without hCG)
HPG axis	Recovery between cycles	Permanently suppressed
Medical follow-up	Rare	Essential (Bhasin 2018)
Monthly cost	High during cycle	Moderate and constant
ASIH risk	Low if correct PCT	Not relevant (already on TRT)

Quand choisir cycle-protocol

The classic cycle is the traditional bodybuilding practice: active period ('blast') with supraphysiological testosterone doses (300-600 mg/week) ± additional compounds over 10-16 weeks, followed by PCT (4-6 weeks) to restart the endogenous HPG axis, then off-window of several months with natural testosterone. Choose it for: (1) seasonal competitive practice (bodybuilding or strongman competitions), (2) long-term preservation of the endogenous HPG axis with recovery windows, (3) preserved fertility (with hCG as PCT bridge if necessary), (4) flexibility (alternating blast and off per objectives). Reference: Bhasin 2001 (dose-response RCT) shows that dose-response is linear up to 300 mg/week then plateaus, justifying cycles 400-600 mg/week for maximum effect. Drawbacks to anticipate (Pope 2014, Endocrine Society): degraded cardiovascular profile during each cycle (HDL crash, hypertension, elevated hematocrit), ASIH risk (Anabolic Steroid Induced Hypogonadism, Coward 2013) if PCT fails, post-cycle fatigue during HPG axis recovery, potential cardiovascular accumulation over years of repeated cycles. Preferable for young users with documented HPG recovery and desire for 'natural' windows.

Quand choisir trt-cruise

TRT-cruise is continuous exogenous testosterone at physiological dose, originally designed to treat confirmed hypogonadism (Bhasin 2018: Endocrine Society guideline). In bodybuilding practice, some users switch to permanent TRT after repeated cycles, or as a hormonal lifestyle choice preferring stability to natural pulsatility. Choose it for: (1) confirmed hypogonadism (T total < 250 ng/dL with symptoms), (2) medically supervised switch after several cycles with difficult HPG recovery, (3) stable hormonal lifestyle choice (no cycle off, no PCT, no fluctuations), (4) elderly user or with contraindication to supraphysiological peaks. Pharmacological profile: testosterone 100-200 mg/week (enanthate or cypionate) in 1-2 injections, sometimes daily SC for maximum stability. ADVANTAGES (Lincoff 2023, RCT TRAVERSE): at physiological dose, TRT does not increase major cardiovascular events vs placebo over 33 months — markedly more favorable cardio profile than a repeated supraphysiological cycle. Drawbacks: permanent commitment (HPG axis does not recover as long as TRT continues), suppressed fertility without hCG as bridge (workaround: hCG 250-500 IU 2× per week in parallel), essential lifelong medical follow-up (quarterly panel hematocrit, lipids, PSA, E2).

Combinaison ?

Classic cycle and TRT-cruise are antinomic protocols: one chooses one OR the other, not both simultaneously. However, a hybrid variant exists: the 'blast and cruise' practice where the user alternates supraphysiological blast phases (300-600 mg/week testo + compounds) and TRT-dose cruise phases (100-150 mg/week) without ever stopping completely. This practice cumulates risks (repeated supraphysiological exposure + continuous HPG axis suppression without recovery) without the advantages (no natural window, no true cardio neutrality). To avoid in first intention. The switch from cycle to TRT-cruise is typically justified by: (1) confirmed ASIH (endogenous T does not recover after several PCTs), (2) medical choice after endocrine evaluation, (3) personal factors (age, quality of life, fertility not sought). TRT-cruise monitoring: quarterly hematocrit panel (target < 52%), lipids, PSA (if > 40 years), E2, T total and free. hCG 250-500 IU 2× per week if fertility to preserve (Anawalt 2019). AI if E2 > 150 pmol/L. Sample TRT transition timeline after chronic cycle failure: W0 last cycle ended 12 weeks ago, T total persistently < 250 ng/dL, W1 endocrinology consultation and complete pituitary/testicular evaluation, W4 TRT initiation at 100 mg/week enanthate + hCG 500 IU 2× per week if fertility relevant, W8 first TRT panel adjustment, W12 stable dose confirmed, lifetime quarterly monitoring schedule established. Sample cycle continuation strategy for younger user: limit to 1 cycle per year, 12-week duration max, clean PCT, off-window > 1.5× blast duration, monitor recovery panels carefully, switch to TRT only if multiple PCTs fail. Cost transparency: TRT clinical ~50-100 €/month long-term, cycle 200-400 € during active windows. Sample baseline panel must include CBC, comprehensive metabolic panel, lipids with apoB, T total, free T, LH, FSH, E2, prolactin, PSA if over 40, sperm analysis if fertility relevant, and resting BP averaged over three days. Echocardiography baseline recommended if cycle history includes more than 3 cumulative blast cycles or any nandrolone/trenbolone exposure.

FAQ

When to switch from cycle to TRT-cruise?: Medical decision based on persistent biological panel. Suggestive criteria: T total < 300 ng/dL at 3 months post-PCT after several cycles, LH < 2 IU/L (non-functional HPG axis), persistent hypogonadism symptoms (fatigue, low libido, depression), repeated unsuccessful PCT attempts. Coward 2013 documents ASIH in chronic users. Endocrinology consultation essential to confirm diagnosis and institute medically supervised TRT. Bhasin 2018 (Endocrine Society) frames indications and protocol.
TRT and fertility?: Incompatible without support. TRT suppresses endogenous testosterone production and therefore spermatogenesis in a few months. To preserve fertility under TRT (Anawalt 2019, Liu 2002): hCG 250-500 IU 2× per week SC in parallel with testosterone to stimulate Leydig cells and maintain spermatogenesis. Alternative: enclomiphene (Androxal-like) 12.5-25 mg/d in monotherapy that maintains endogenous production. For users wishing to procreate, these protocols preserve reproductive function while ensuring satisfactory T levels.
Cardiovascular profile: cycle vs TRT?: Very different. TRT at physiological dose is cardio-neutral (Lincoff 2023, RCT TRAVERSE on 5,246 hypogonadic men at risk, 33-month follow-up). No significant increase in major cardio events vs placebo, slight increase in atrial fibrillation and venous thromboembolism (low incidence). Cumulated supraphysiological cycle: hypertension, severe dyslipidemia, left ventricular hypertrophy (Baggish 2017, Smit 2022). For users > 35 years or with cardio family history, clean TRT markedly more favorable than repeated cycles.
How many cycles before probable ASIH?: Variable per individual, but Coward 2013 and Rasmussen 2016 document cumulative risk increasing with: (1) number of total cycles (> 3-5 cumulated cycles), (2) duration of individual cycles (> 16 weeks), (3) strong-suppression compounds (nandrolone, trenbolone), (4) neglected or incomplete PCTs. Statistically, about 20-30% of chronic users (> 5 years of repeated cycles) switch to persistent hypogonadism requiring permanent TRT. To minimize: short cycles, clean PCTs, off-windows > 1.5× the on-block duration, regular biological monitoring.
Compared cost?: TRT-cruise (clinical): 50-150 €/month per country and formula (testosterone + hCG + AI). Medical follow-up included if TRT prescribed. Classic bodybuilder cycle: 200-500 € during 12-16 weeks of blast (testo + compounds + AI + PCT), free during off. Over 12 months: TRT ≈ 1500 € constant; cycle = 800-1500 € with high concentration on blast periods. Short-term, cycle may seem cheaper if infrequent. Long-term (10+ years), clinical TRT is generally more economical and more predictable.
Does clean PCT guarantee recovery?: No, but maximizes chances. A well-conducted PCT (hCG 1500 IU EOD × 10 d + clomid 50/25/25/25 mg + nolvadex 40/20/20/20 mg over 4-6 weeks) allows 70-90% of users to recover endogenous T > 400 ng/dL at 3 months post-PCT (Rahnema 2014). But 10-30% develop partial or complete ASIH, particularly after long cycles or nandrolone/trenbolone. Negative predictive factors: age > 35 years, comorbidities, repeated cycles > 5, low pre-cycle baseline T. Systematic pre-cycle and post-PCT biological panel to identify at-risk users.
TRT in young user (< 30 years)?: Delicate question. If confirmed primary hypogonadism (Klinefelter, post-orchidectomy, etc.), lifelong TRT justified. If ASIH secondary to cycles, the decision of permanent TRT before 30 years commits the user to 50+ years of treatment with impacts (fertility, medical dependence, lifelong follow-up). Several endocrinologists recommend exhausting restart options (prolonged clomid, hCG, enclomiphene) before switching to permanent TRT. Specialist consultation essential to assess long-term benefit/constraint ratio.

Classic Cycle vs TRT-cruise: complete comparison (protocols, philosophies)

Critère	cycle-protocol	trt-cruise
Duration	10-16 wk (cycle) + PCT	Permanent (TRT)
Testo dose	300-600 mg/week (supraphysio)	100-200 mg/week (physio)
Cardiovascular profile	Variable per dose	Neutral (Lincoff 2023)
Fertility	Recoverable post-PCT	Suppressed (without hCG)
HPG axis	Recovery between cycles	Permanently suppressed
Medical follow-up	Rare	Essential (Bhasin 2018)
Monthly cost	High during cycle	Moderate and constant
ASIH risk	Low if correct PCT	Not relevant (already on TRT)

Quand choisir cycle-protocol

Quand choisir trt-cruise

Combinaison ?

FAQ

When to switch from cycle to TRT-cruise?: Medical decision based on persistent biological panel. Suggestive criteria: T total < 300 ng/dL at 3 months post-PCT after several cycles, LH < 2 IU/L (non-functional HPG axis), persistent hypogonadism symptoms (fatigue, low libido, depression), repeated unsuccessful PCT attempts. Coward 2013 documents ASIH in chronic users. Endocrinology consultation essential to confirm diagnosis and institute medically supervised TRT. Bhasin 2018 (Endocrine Society) frames indications and protocol.
TRT and fertility?: Incompatible without support. TRT suppresses endogenous testosterone production and therefore spermatogenesis in a few months. To preserve fertility under TRT (Anawalt 2019, Liu 2002): hCG 250-500 IU 2× per week SC in parallel with testosterone to stimulate Leydig cells and maintain spermatogenesis. Alternative: enclomiphene (Androxal-like) 12.5-25 mg/d in monotherapy that maintains endogenous production. For users wishing to procreate, these protocols preserve reproductive function while ensuring satisfactory T levels.
Cardiovascular profile: cycle vs TRT?: Very different. TRT at physiological dose is cardio-neutral (Lincoff 2023, RCT TRAVERSE on 5,246 hypogonadic men at risk, 33-month follow-up). No significant increase in major cardio events vs placebo, slight increase in atrial fibrillation and venous thromboembolism (low incidence). Cumulated supraphysiological cycle: hypertension, severe dyslipidemia, left ventricular hypertrophy (Baggish 2017, Smit 2022). For users > 35 years or with cardio family history, clean TRT markedly more favorable than repeated cycles.
How many cycles before probable ASIH?: Variable per individual, but Coward 2013 and Rasmussen 2016 document cumulative risk increasing with: (1) number of total cycles (> 3-5 cumulated cycles), (2) duration of individual cycles (> 16 weeks), (3) strong-suppression compounds (nandrolone, trenbolone), (4) neglected or incomplete PCTs. Statistically, about 20-30% of chronic users (> 5 years of repeated cycles) switch to persistent hypogonadism requiring permanent TRT. To minimize: short cycles, clean PCTs, off-windows > 1.5× the on-block duration, regular biological monitoring.
Compared cost?: TRT-cruise (clinical): 50-150 €/month per country and formula (testosterone + hCG + AI). Medical follow-up included if TRT prescribed. Classic bodybuilder cycle: 200-500 € during 12-16 weeks of blast (testo + compounds + AI + PCT), free during off. Over 12 months: TRT ≈ 1500 € constant; cycle = 800-1500 € with high concentration on blast periods. Short-term, cycle may seem cheaper if infrequent. Long-term (10+ years), clinical TRT is generally more economical and more predictable.
Does clean PCT guarantee recovery?: No, but maximizes chances. A well-conducted PCT (hCG 1500 IU EOD × 10 d + clomid 50/25/25/25 mg + nolvadex 40/20/20/20 mg over 4-6 weeks) allows 70-90% of users to recover endogenous T > 400 ng/dL at 3 months post-PCT (Rahnema 2014). But 10-30% develop partial or complete ASIH, particularly after long cycles or nandrolone/trenbolone. Negative predictive factors: age > 35 years, comorbidities, repeated cycles > 5, low pre-cycle baseline T. Systematic pre-cycle and post-PCT biological panel to identify at-risk users.
TRT in young user (< 30 years)?: Delicate question. If confirmed primary hypogonadism (Klinefelter, post-orchidectomy, etc.), lifelong TRT justified. If ASIH secondary to cycles, the decision of permanent TRT before 30 years commits the user to 50+ years of treatment with impacts (fertility, medical dependence, lifelong follow-up). Several endocrinologists recommend exhausting restart options (prolonged clomid, hCG, enclomiphene) before switching to permanent TRT. Specialist consultation essential to assess long-term benefit/constraint ratio.